Evidence map›Paper›PMID 42455487›Full record

ArticleAnnals of surgical oncology2026

Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes.

Wen-Fang Tang, Si-Qi Huang, Hong-Ji Li, Xuan Tang, Yi Liang, Wei-Zhao Huang, Hai-Ming Jiang, Jian Su, Wen-Zhao Zhong

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wen-Fang TangGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Si-Qi HuangGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Hong-Ji LiGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Xuan TangDepartment of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.
Yi LiangDepartment of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.
Wei-Zhao HuangDepartment of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.
Hai-Ming JiangDepartment of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.
Jian SuGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Wen-Zhao ZhongGuangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. syzhongwenzhao@scut.edu.cn.

Funding

Project of National Natural Science Foundation of China 82203421
6 · The paper itself

Abstract

backgroundAlthough perioperative chemoimmunotherapy is standard for resectable non-small cell lung cancer (NSCLC), evidence in rare histological subtypes remains scarce owing to their low incidence and limited representation in clinical trials. PATIENTS AND

methodsWe retrospectively analyzed 77 patients with resectable rare-subtype lung cancer (excluding adenocarcinoma, squamous cell carcinoma and small cell lung cancer) who received neoadjuvant chemoimmunotherapy followed by surgery at Guangdong Provincial People's Hospital between January 2019 and October 2025. Pathological response, predictive biomarkers, immune microenvironment dynamics, and survival were assessed.

resultsThe major pathological response (MPR) rate was 48.1% (37/77), with 22.1% achieving pathological complete response (pCR). MPR was strongly predicted by PD-L1 expression ≥ 75% and ΔSUV

conclusionsNeoadjuvant chemoimmunotherapy demonstrates encouraging efficacy in rare subtypes of lung cancer, with distinct predictive biomarkers and survival patterns, warranting further prospective validation.

Indexed as

Clinical outcomesImmune microenvironmentLung cancerNeoadjuvant chemoimmunotherapyRare histological subtypes

Identifiers

PMID42455487

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.